T. Kindler - Med Dept 3, Univ Mainz | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 17 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study

T. H. Bruemmendorf,C. Gambacorti-Passerini,T. Kindler,S. Saussele,D. W. Kim, Y. T. Goh,I Dyagil,K. Pagnano,A. Batai,A. G. Turkina,E. Leip,S. Purcell,

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用3浏览0引用

Bosutinib (BOS) for previously treated patients with Philadelphia chromosome-positive (Ph plus ) leukemia: >= 8-year update of a phase 1/2 study

T. H. Bruemmendorf, J. E. Cortes,P. Schafhausen,T. Kindler,S. Saussele,M. C. Mueller, Y. T. Goh,M. Yilmaz, R. B. Klisovic,S. Purcell, A. Viqueira,E. Leip,

ONCOLOGY RESEARCH AND TREATMENT（2020）

引用0浏览0引用

Transcriptional effectors of etoposide contribute to cytotoxicity in AML cell lines

P. More, U. Goedtel-Armbrust,V. Shah, M. Mathaes,T. Kindler, M. Andrade,L. Wojnowski

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY（2019）

引用0浏览0引用

THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA

S. Scheinost,J. Lu,L. Wagner, J. Huellein,T. Walther,L. Sellner, A. Theocharides, B. Bornhäuser, M. Kühn,T. Kindler,F. Florence Nguyen-Khac, M. Crespo Maull,

Hematological Oncology（2019）

引用0浏览0引用

MDM2 and PARP as therapeutic targets in acute myeloid leukemia

S. Zeuner,V Shah, P. S. Haehnel, J. Szybinski, D. Strand,M. Theobald, M. W. M. Kuehn,T. Kindler

ONCOLOGY RESEARCH AND TREATMENTno. SUPnan (2018): 77-78

引用0浏览0引用

Randomized Phase 2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Haboring DNA Repair Deficiencies (DKTK/NCT-PMO-1603, TOP-ART)

R. Schlenk, S. Groeschel, C. Heilig,S. Bauer,G. Folprecht, C. Brandts,N. von Bubnoff,T. Kindler,P. Horak,C. Heining,D. Richter, A. Eisenmenger,

ONCOLOGY RESEARCH AND TREATMENT（2018）

引用0浏览0引用

Epidemiological, genetic and clinical characterization of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) (NCT01252485)

G. Nagel,D. Weber, E. Fromm, S. Erhardt,M. Luebbert,W. Fiedler,T. Kindler,J. Krauter,P. Brossart, A. Kuendgen,H. Salih,J. Westermann,

ONCOLOGY RESEARCH AND TREATMENT（2017）

引用0浏览0引用

Aberrant NCAM Expression as a Therapeutic Target in AML

D. Sasca, A. Schueler, J. Szybinski,O. Kriege,P. Haehnel, J. Heidelberger,A. Dolnik, W. H. Gebhardt,G. Reid,M. Theobald,P. Beli, L. Bullinger,

ANNALS OF HEMATOLOGY（2017）

引用0浏览0引用

DNMT3A mutations (DNMT3Amut) in acute myeloid leukemia (AML): monitoring of minimal residual disease (MRD). A study of the AML Study Group (AMLSG)

I Gaidzik V.,D. Weber,P. Paschka,S. Krieger, A. Kaumanns,J. Kroenke,S. Kapp-Schwoerer,C-H Koehne,H-A Horst,I. G. H. Schmidt-Wolf,G. Held,A. Kuendgen,

HAEMATOLOGICA（2015）

引用0浏览0引用

Targeting Connective Tissue Growth Factor (CTGF) inhibits cell adhesion-mediated drug resistance in acute myeloid leukemia

S. V. Pante, S. J. Henninger,K. Kunz,D. Sasca,M. Theobald,T. Kindler

ONCOLOGY RESEARCH AND TREATMENTno. SUPnan (2014): 130-131

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn